Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2 | P10415 | 7/20 | 0.47 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | MYC | P01106 | 1/20 | 0.45 |
| ▸ | MAX | P61244 | 1/20 | 0.45 |
| ▸ | SYK | P43405 | 1/20 | 0.42 |
| ▸ | PPARA | Q07869 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.41 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.41 |
| ▸ | CTSV | O60911 | 1/20 | 0.41 |
| ▸ | CTSL | P07711 | 1/20 | 0.41 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.40 |
| ▸ | APP | P05067 | 1/20 | 0.40 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.40 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.40 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22120986 | 0.90 | BCL2 (0.47) | BCL2MCL1ATMMYCMAX | |
| SCHEMBL29162420 | 0.88 | ACE (0.54) | BCL2MCL1PPARACTSLPTPN1 | |
| SCHEMBL29919451 | 0.86 | BCL2 (0.43) | BCL2MCL1ATMMYCMAX | |
| SCHEMBL29919848 | 0.86 | BCL2 (0.52) | BCL2MCL1PPARACTSLITGA4 | |
| SCHEMBL1731189 | 0.86 | BCL2 (0.52) | BCL2MCL1PPARACTSLITGA4 | |
| SCHEMBL31232679 | 0.83 | BCL2 (0.41) | BCL2MCL1ATMMYCMAX | |
| SCHEMBL22154629 | 0.83 | BCL2 (0.41) | BCL2MCL1ATMMYCMAX | |
| SCHEMBL22154247 | 0.83 | BCL2 (0.47) | BCL2MCL1ATMSYKPPARA | |
| SCHEMBL28642378 | 0.83 | BCL2 (0.47) | BCL2MCL1ATMSYKPPARA | |
| SCHEMBL10214923 | 0.82 | ATM (0.50) | BCL2ATMSYKPPARAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12168648-B2 | Opioid receptor modulators | EPIODYNE, INC. (US) | 2024-12-17 | — | — | US | disclosed |
| US-20240092746-A1 | OPIOID RECEPTOR MODULATORS | EPIODYNE, INC. | 2024-03-21 | — | — | US | disclosed |
| EP-4320105-A1 | OPIOID RECEPTOR MODULATORS | Epiodyne, Inc. (US) | 2024-02-14 | — | — | EP | disclosed |
| US-11634396-B2 | Opioid receptor modulators | EPIODYNE, INC. (US) | 2023-04-25 | — | — | US | disclosed |
| US-20220356157-A1 | OPIOID RECEPTOR MODULATORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-11-10 | — | — | US | disclosed |
| WO-2022216750-A1 | OPIOID RECEPTOR MODULATORS | EPIODYNE, INC. (US) | 2022-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240092746-A1 | OPIOID RECEPTOR MODULATORS | OPRM1, OPRK1, OPRL1 | BCL2 4555/4885MCL1 4355/4885ATM 4757/4885 |
| US-12168648-B2 | Opioid receptor modulators | OPRM1, OPRK1, OPRL1 | BCL2 4555/4885MCL1 4355/4885ATM 4757/4885 |
| US-11634396-B2 | Opioid receptor modulators | OPRM1, OPRK1, OPRL1 | BCL2 4555/4885MCL1 4355/4885ATM 4757/4885 |
| US-20220356157-A1 | OPIOID RECEPTOR MODULATORS | OPRM1, OPRK1, OPRL1 | BCL2 4555/4885MCL1 4355/4885ATM 4757/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.